Neutralizing Power of Serum Antibodies - 2

Recruiting now · Not applicable

Conditions studied: COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination, Serum, Mucosal Immunity

In brief

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.

Key facts

Study ID

NCT07085611

Run by

Centre Hospitalier Régional d'Orléans

People needed

30

Starts

2025-08-22

Expected to finish

2035-07-11

Last updated by the study team

2025-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years)
• Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
• Patients have provided written informed consent

You may not qualify if…

• Persons under guardianship or curatorship
• Persons under legal protection,
• Persons persons deprived of liberty
• Persons not affiliated to a social security scheme
• Pregnant or breastfeeding women

Where it is running

• CHU Orléans — Orléans, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.